ArticlePloS one2021
Peak expiratory flow rate and sarcopenia risk in older Indonesian people: A nationwide survey.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Genetic association and causal inference between lung function and venous thromboembolism.Respiratory research · 2023Pooled it
- Association of respiratory function with sarcopenia in older outpatients: cross-sectional analysis of baseline data from the JUSTICE-TOKYO prospective cohort study.European geriatric medicine · 2026Article
- Combined Effect of Sarcopenia and Impaired Respiratory Function on All-Cause Death: A Nationwide Cohort Study.Journal of cachexia, sarcopenia and muscle · 2026Article
- Association between physical activity, peak expiratory flow, and cognitive function in aging: a cross-sectional analysis.BMC geriatrics · 2024Article
- Establishing an optimal diagnostic criterion for respiratory sarcopenia using peak expiratory flow rate.Aging clinical and experimental research · 2024Article
- Associations of sarcopenia with peak expiratory flow among community-dwelling elderly population: based on the China Health and Retirement Longitudinal Study (CHARLS).European geriatric medicine · 2024Article
- Diagnostic performance of calf circumference, SARC-F, and SARC-CalF for possible sarcopenia screening in Indonesia.Scientific reports · 2023Article
- Psoas muscle mass index and peak expiratory flow as measures of sarcopenia: relation to outcomes of elderly patients with resectable esophageal cancer.Frontiers in oncology · 2023Article
- Associations between the muscle quality index and adult lung functions from NHANES 2011-2012.Frontiers in public health · 2023Article
- Article
- Daytime napping, comorbidity profiles, and the risk of sarcopenia in older individuals.Frontiers in physiology · 2022Article
- Association between Serum Zinc Levels and Clinicopathological Characteristics in Patients with Gastric Cancer.Gastrointestinal tumorsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reduced peak expiratory flow is a common physiological change in older individuals and age is an important predictor for sarcopenia. We analyzed nationwide survey data to determine the relationship between peak expiratory flow rate and sarcopenia in older Indonesians. Community-dwelling Indonesian individuals aged ≥60 years (n = 2422; mean age = 67.21 y) from the fifth-wave data of the Indonesian Family Life Survey was selected. Sarcopenia was diagnosed based on handgrip strength, gait speed, and appendicular skeletal muscle mass measurements. Peak expiratory flow rates (PEFRs) were categorized according to their percentage of predicted flow rates as <50%, 50% to 80%, and >80%. Confounders previously determined to be associated with sarcopenia occurrence were included. Sarcopenia prevalence was 50.25%. After adjustment for confounders, PEFRs of <50% and 50% to 80% were associated with an increased sarcopenia risk (odds ratio = 5.22 and 1.88, respectively) compared with PEFRs of >80%. Poor lung function was independently associated with sarcopenia occurrence. Future studies should explore the usefulness of PEFR as a risk factor of sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.